Actinogen Medical (ASX:ACW) has announced it has enrolled the final patient in XanADu, its Phase 2 clinical trial of Xanamem in the treatment of patients with mild Alzheimer’s disease.
A total of 186 patients have been enrolled in the study. The company said this surpasses its initial target of 174 patients.
XanADu is a randomised, double-blind, multi-centre clinical study comparing Xanamem to placebo in patients with mild dementia due to Alzheimer’s disease.
XanADu is the largest and most comprehensive international Alzheimer’s treatment trial run by an Australian biotech company.
The final patient will complete the trial in four months, following three months of treatment with Xanamem or placebo followed by a one-month observation period off-treatment. All the trial data will then be collated, reviewed, and quality controlled, before being analysed, said Actinogen in a statement.
The company said it is on track to report the results during the second quarter of 2019.
According to CEO Dr Bill Ketelbey, “Enrolment of the final patient into XanADu represents a major milestone for Actinogen, as we now have certainty on the timeline to completion of the trial and to the reporting out of the results. We eagerly await the trial outcomes as they may represent a significant step forward in developing an effective new treatment approach for patients with mild Alzheimer’s disease, and could make a substantial impact in the future treatment of this devastating disease.
“I’d like to thank all patients who participated in this trial, their families and carers, and all the trial sites around the world. Their commitment to medical research, and to extending our understanding of cognitive impairment and Alzheimer’s disease, benefits society as a whole and could help uncover important new drugs to treat these diseases.”